الفهرس 
Colorectal CancerOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. Accumulation of varieties of epigenetic changes, including miRNA regulation, is one of the fundamental processes driving CRC initiation and progression. Mir-92ahas been reported in several studies as an oncogene, and particularly in colorectal cancer. Aim: This study was conducted to evaluate the clinical utility of the circulating miRNA-92a in patients with CRC in comparison to CA 19.9 and CEA as a conventional marker of CRC.Materials and Methods: This is a pilot retrospective case-control study. We quantified serum Mir-92aexpression level using qRT-PCR in 20CRC patients (group I), 20 patients with inflammatory bowel disease (IBD)(group II) and another 10 healthy controls (groupIII) in comparison to CEA and CA19.9 as conventional markers of CRC used in clinical practice. Results: Expression level of MiRNA-92a was significantly higher among the CRC group compared to the IBD and control groups (H:18.3, P-value<0.01).MiRNA-92a expression levels at cutoff 17 log10 was superior in early diagnosis of CRC patients as its diagnostic sensitivity was 90% and specificity was 85% versus CEA which at a cutoff 25 U/mL displayed diagnostic sensitivity 90% and diagnostic specificity 30% whileCA19.9 at a cutoff 20 U/mL displayed diagnostic sensitivity and specificity of 30% and 90%, respectively. Multi-ROC between MiRNA-92a and serum CEA revealed better sensitivity and specificity (95 and 90%, respectively).In addition, a significant positive correlation between CA19.9 levels and miRNA-92a expression levels was detected in CRC patients (rs=0.62,p<0.01). Conclusion: MiRNA-92a level is a promising diagnostic biomarkers for early prediction of CRC.